These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33580792)

  • 1. Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey.
    Koskinas KC; Catapano AL; Baigent C; Tokgozoglu L; Mach F
    Eur J Prev Cardiol; 2022 Feb; 28(18):2030-2037. PubMed ID: 33580792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
    Şimşek B; İnan D; Çınar T; Cagdas-Yumurtaş A; Ozan-Tanık V; Zeren G; İlker-Avcı İ; Yücel-Karabay C; Güngör B; Tokgozoğlu L
    Rev Invest Clin; 2021 Nov; 73(3):371-378. PubMed ID: 34098569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
    Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
    Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
    Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
    Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
    De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
    Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
    Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
    Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project.
    Laufs U; Catapano AL; De Caterina R; Schiele F; Sionis A; Zaman A; Jukema JW
    Vascul Pharmacol; 2023 Feb; 148():107141. PubMed ID: 36626974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
    Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
    Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice - one center study.
    Cecha P; Chromik A; Piotrowska I; Zabojszcz M; Dolecka-Ślusarczyk M; Siudak Z
    Folia Med Cracov; 2021 Sep; 61(3):43-54. PubMed ID: 34882663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Did the Updated 2019 European Society of Cardiology/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study.
    Başaran Ö; Doğan V; Mert KU; Özlek B; Özlek E; Çelik O; Çil C; Özdemir İH; Rencüzoğulları İ; Özpamuk Karadeniz F; Tekinalp M; Aşkın L; Demirelli S; Gencer E; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Çinier G; Halil Akay K; Pekel N; Mert GÖ; Şenol U; Demir V; İnci S; Derviş E; Biteker M; Kayıkçıoğlu M
    Anatol J Cardiol; 2023 Feb; 27(2):78-87. PubMed ID: 36747449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments.
    Yang YS; Lee SY; Kim JS; Choi KM; Lee KW; Lee SC; Cho JR; Oh SJ; Kim JH; Choi SH
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):367-376. PubMed ID: 32615721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations.
    Zeitouni M; Sabouret P; Kerneis M; Silvain J; Collet JP; Bruckert E; Montalescot G
    Eur Heart J Cardiovasc Pharmacother; 2021 Jul; 7(4):324-333. PubMed ID: 32652000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
    Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
    Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study.
    Harris DE; Lacey A; Akbari A; Torabi F; Smith D; Jenkins G; Obaid D; Chase A; Gravenor M; Halcox J
    Eur J Prev Cardiol; 2021 Jul; 28(8):854-861. PubMed ID: 34298561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.